Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate 4D Molecular Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding 4D Molecular Therapeutics Inc’s stock price such as:

• 4D Molecular Therapeutics Inc’s current stock price and volume
• Why 4D Molecular Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for FDMT from analysts
• FDMT’s stock price momentum as measured by its relative strength

About 4D Molecular Therapeutics Inc (FDMT)

Before we jump into 4D Molecular Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Want to learn more about 4D Molecular Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about 4D Molecular Therapeutics Inc.

What Caused 4D Molecular Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 28, 2024, there were 2 analysts who downgraded 4D Molecular Therapeutics Inc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate 4D Molecular Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on 4D Molecular Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

4D Molecular Therapeutics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about 4D Molecular Therapeutics Inc (FDMT) by visiting AAII Stock Evaluator.

Relative Price Strength of 4D Molecular Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 28, 2024, 4D Molecular Therapeutics Inc has a weighted four-quarter relative price strength of 17.96%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how 4D Molecular Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

4D Molecular Therapeutics Inc Stock Price: Bottom Line

As of April 1, 2024, 4D Molecular Therapeutics Inc’s stock price is $30.01, which is down 5.81% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like 4D Molecular Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.